LENZ Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LENZ research report →
About the company
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia.
- CEO
- Evert Schimmelpennink
- IPO
- 2024
- Employees
- 6
- HQ
- Solana Beach, CA, US
Price Chart
- Market Cap
- $184.68M
- P/E
- -1.64
- P/S
- 8.80
- P/B
- 0.75
- EV/EBITDA
- -1.49
- Div Yield
- 0.00%
- Gross Margin
- 91.16%
- Op Margin
- -563.83%
- Net Margin
- -519.30%
- ROE
- -46.82%
- ROIC
- -47.88%
- Revenue
- $19.09M · 0.00%
- Net Income
- $-82,127,000 · -65.02%
- EPS
- $-2.85 · -21.79%
- Op Income
- $-91,138,000
- FCF YoY
- -16.94%
- 52W High
- $50.40
- 52W Low
- $5.23
- 50D MA
- $7.53
- 200D MA
- $18.49
- Beta
- 1.62
- Avg Volume
- 785.34K
Get TickerSpark's AI analysis on LENZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 22,100 |
| Jun 15, 26 | George Jeffrey P. | other | 22,100 |
| Jun 15, 26 | Drapkin Kimberlee C | other | 22,100 |
| Jun 15, 26 | MCCOLLUM JAMES W | other | 22,100 |
| Jun 15, 26 | Thunen Shelley B | other | 22,100 |
| Jun 15, 26 | Guerard Frederic | other | 22,100 |
| Jun 15, 26 | Scheiner Zachary | other | 22,100 |
| Mar 27, 26 | George Jeffrey P. | buy | 5,592 |
| Mar 27, 26 | Schimmelpennink Evert B. | buy | 28,089 |
| Mar 27, 26 | Chevallard Daniel R. | buy | 7,500 |
Our LENZ coverage
Recent articles, reports, and earnings notes.
No research on LENZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LENZ report →Similar companies
Peers in the same neighborhood.